TAGline May 2020
Realizing the Right to Science: When we started to put together this issue of TAGline, we had no idea that COVID-19 was about to make its appearance and wreak havoc on every country of the world.
Treatment Action Group and the PrEP4All Collaboration Respond to Reported Remdesivir Results for COVID-19
Treatment Action Group (TAG) and the PrEP4All Collaboration welcome results from randomized controlled trials of therapies for COVID-19, but are seriously concerned about claims that data from a National Institutes of Allergy and Infectious Diseases (NIAID) study of the Gilead drug remdesivir...
An Activist’s Guide to Rifapentine for the Treatment of TB Infection
The English version of this publication updated 2024. Please refer to the earlier versions on this page if you need languages other than English. English version updated April 2020. The updated guide reflects new information from recently completed clinical…
Open Letter to the Diagnostics Supply Consortium
On 24 April 2020, advocates sent an open letter to the Diagnostics Supply Consortium calling for a higher level of global coordination, transparency, and accountability to ensure sustainable and equitable access to molecular diagnostic testing for COVID-19...
Global Health and Human Rights Organizations Denounce Trump Administration Decision to Pull Commitments to WHO during COVID-19 Crisis
AVAC, Health GAP, Knowledge Ecology International (KEI), and Treatment Action Group (TAG) strongly condemn the Trump Administration’s decision to halt funding to the World Health Organization (WHO) in the midst of the urgent COVID-19 global health crisis.
Treatment Action Group Celebrates New Guidance on the Right to Science by Global Human Rights Body
Treatment Action Group (TAG) celebrates publication of the General Comment on “the human right of everyone to participate in and to enjoy the benefits of scientific progress and its applications” (the right to science), and calls the attention of grassroots activists and global civil society working on health to this landmark document.
From Fair Share to Fair Shot: Capitalizing on Opportunities to Ensure Success of U.S.-Government-Funded TB Research
This policy brief discusses the impact of underfunding TB research led by U.S. government agencies. The brief explores several prospective opportunities for TB R&D that would be made possible with increased funding, with recommendations on where policymakers and appropriators can make key investments to U.S. government agencies to advance crucial science on TB diagnostics, treatments, and vaccines.
Treatment Action Group Statement on BCG Vaccine and COVID-19
Treatment Action Group (TAG) cautions that widespread media reports that the baccille Calmette–Guérin (BCG) vaccine may be protective against COVID-19 need to be read with caution.
Fair Pricing for Cepheid Xpert Tests (COVID-19, HIV, TB, HCV)
On Friday, April 3, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF), and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, TB, HIV, HCV and other diseases.
TAG Statement on WHO Updated TB Preventive Therapy Guidance
Last week, Treatment Action Group was pleased to receive the World Health Organization’s (WHO) update to its guidance on TB preventive therapy (TPT).